• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

FDA granted approval to Pembrolizumab for Colorectal Cancer Treatment

September 8, 2020
-
News
-
Posted by seoaccount medivisual
Pembrolizumab-for-colorectal-cancer-treatment-admac

For the first-line treatment of patients with unresectable or metastatic MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient) colorectal cancer, the United States Food and Drug Administration (US FDA) granted its approval to pembrolizumab on 29 June 2020.

A multicentre, open-label, active-controlled, randomized study recruiting 307 patients having MSI-H/dMMR colorectal cancer was conducted. Using polymerase chain reaction (PCR) or immunohistochemistry (IHC), MSI or MMR tumor status was assessed locally.

Participants were randomly assigned to receive either treatment with pembrolizumab 200 mg intravenously (iv.) every three weeks or treatment with investigator’s choice of mFOLFOX6/FOLFIRI ± bevacizumab or cetuximab administered iv. every two weeks. At the time of disease progression, the patients randomized to chemotherapy were administered with pembrolizumab.

Progression-free survival (PFS) and overall survival (OS) were the main efficacy outcome measures. Median PFS was more in the pembrolizumab group than the chemotherapy group as shown in the following table:

Pembrolizumab group Chemotherapy group
Median PFS 16.5 months 8.2 months

The OS data were not mature at the time of the PFS analysis. In ≥20% of patients receiving pembrolizumab as a single agent, the most common adverse reactions reported are abdominal pain, musculoskeletal pain, fatigue, reduced appetite, diarrhea, pruritus, nausea, pyrexia, rash, cough, constipation, and dyspnea.

For managing colorectal cancer, the dose of pembrolizumab is suggested to be 200 mg every 3 weeks or 400 mg every 6 weeks. Pembrolizumab is a promising therapeutic agent for metastatic MSI-H or dMMR colorectal cancer.

Such as these, you can also explore and study regarding other approved chemotherapeutic drugs, Infigratinib, Avelumab, Bortezomib.

Source FDA
Link: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer#:~:text=On%20June%2029%2C%202020%2C%20the,deficient%20(dMMR)%20colorectal%20cancer. [Last accessed on: 14 July, 2020]
Original title of the article FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer
← PREVIOUS POST
Obesity and cancer: How deleterious is the relationship?
NEXT POST →
Ramucirumab plus erlotinib receives FDA approval to treat metastatic NSCLC

Related News

Other posts that you should not miss.
alcohol-consumption-and-cancer-admac

An association between Alcohol consumption and Cancer

November 25, 2020
-
News

Extreme alcohol drinking in any way is injurious to health. It is said that drinking in moderate amounts can be beneficial for cardiovascular health. Moderation alcohol drinking defined …

Read More →
Posted by admin
3 MIN READ
aging-and-cancer-admaconcology

Cancer preventive tips in aged people

November 19, 2020
-
News

Cancer is the reason behind 1 in every 6 deaths around the world. The ratio is more than deaths caused by tuberculosis, AIDS, and malaria combined. The rate …

Read More →
Posted by seoaccount medivisual
5 MIN READ
cloves-and-cancer-prevention-admaconcology

Clove: A valuable spice effective for cancer prevention

October 6, 2020
-
News

Cancer is emerging as the foremost health problem globally. Every year, the number of cancer patients just keep escalating at a terrifying rate. Also, there has been a …

Read More →
Posted by seoaccount medivisual
4 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
FDA approves Pembrolizumab for Colorectal Cancer Treatment | Admaconcology